Madrigal Pharmaceuticals

Historical price data

Madrigal Pharmaceuticals' mission is to deliver novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious and progressive liver disease with high unmet need. The company's landmark achievement is the U.S. and EU approval of resmetirom, the first-ever therapy for MASH with significant fibrosis, stemming from its pioneering work on thyroid hormone receptor-beta agonism. Madrigal's strategy involves building a fully integrated commercial biopharma company to capture the immense MASH market opportunity while advancing its clinical pipeline into additional liver and metabolic disorders. This positions Madrigal as the definitive first-mover in a multi-billion dollar therapeutic arena.

Selective thyroid hormone receptor-beta (THR-β) agonism, a liver-targeted mechanism that regulates lipid metabolism, reduces inflammation, and directly targets fibrosis.

Madrigal's resmetirom is the only approved MASH therapy, but faces upcoming competition from FGF21 analogs (89bio, Akero) and incretin-based therapies (Viking, Novo Nordisk, Eli Lilly). Its oral administration and direct anti-fibrotic action are key differentiators, but competitors may offer superior efficacy on metabolic parameters or weight loss.